Evarrest

RSS

Withdrawn

This medicine's authorisation has been withdrawn

human fibrinogen / human thrombin
MedicineHumanWithdrawn

Latvian is available via eTranslation, the European Commission's machine translation service.

Translate to Latvian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 15 November 2017, the European Commission withdrew the marketing authorisation for Evarrest (human fibrinogen / human thrombin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Omrix Biopharmaceuticals N. V., which notified the European Commission of its decision to permanently discontinue the marketing of the product in the EU for commercial reasons. 

Evarrest was granted marketing authorisation in the EU on 25 September 2013 for the treatment of haemostasis and as an adjunct to haemostasis in bleeding.

The European Public Assessment Report (EPAR) for Evarrest is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (597.14 KB - PDF)

Skatīt

español (ES) (515.07 KB - PDF)

Skatīt

čeština (CS) (578.52 KB - PDF)

Skatīt

dansk (DA) (518.89 KB - PDF)

Skatīt

Deutsch (DE) (516.28 KB - PDF)

Skatīt

eesti (ET) (518.26 KB - PDF)

Skatīt

ελληνικά (EL) (600.8 KB - PDF)

Skatīt

français (FR) (518 KB - PDF)

Skatīt

hrvatski (HR) (535.13 KB - PDF)

Skatīt

italiano (IT) (514.66 KB - PDF)

Skatīt

latviešu (LV) (593.61 KB - PDF)

Skatīt

lietuvių (LT) (538.4 KB - PDF)

Skatīt

magyar (HU) (571.9 KB - PDF)

Skatīt

Malti (MT) (577.35 KB - PDF)

Skatīt

Nederlands (NL) (514.67 KB - PDF)

Skatīt

polski (PL) (576.8 KB - PDF)

Skatīt

português (PT) (536.9 KB - PDF)

Skatīt

română (RO) (1020.06 KB - PDF)

Skatīt

slovenčina (SK) (100.5 KB - PDF)

Skatīt

slovenščina (SL) (567.85 KB - PDF)

Skatīt

suomi (FI) (513.9 KB - PDF)

Skatīt

svenska (SV) (514.56 KB - PDF)

Skatīt

Product information

български (BG) (1.55 MB - PDF)

Skatīt

español (ES) (896.44 KB - PDF)

Skatīt

čeština (CS) (1.51 MB - PDF)

Skatīt

dansk (DA) (813.54 KB - PDF)

Skatīt

Deutsch (DE) (845.01 KB - PDF)

Skatīt

eesti (ET) (787.41 KB - PDF)

Skatīt

ελληνικά (EL) (1.55 MB - PDF)

Skatīt

français (FR) (818.58 KB - PDF)

Skatīt

hrvatski (HR) (898.08 KB - PDF)

Skatīt

italiano (IT) (816.34 KB - PDF)

Skatīt

latviešu (LV) (1.31 MB - PDF)

Skatīt

lietuvių (LT) (910.1 KB - PDF)

Skatīt

magyar (HU) (1.15 MB - PDF)

Skatīt

Malti (MT) (1.31 MB - PDF)

Skatīt

Nederlands (NL) (827.81 KB - PDF)

Skatīt

polski (PL) (1.32 MB - PDF)

Skatīt

português (PT) (818.67 KB - PDF)

Skatīt

română (RO) (934.43 KB - PDF)

Skatīt

slovenčina (SK) (1.32 MB - PDF)

Skatīt

slovenščina (SL) (1.25 MB - PDF)

Skatīt

suomi (FI) (923.42 KB - PDF)

Skatīt

svenska (SV) (864.7 KB - PDF)

Skatīt

Íslenska (IS) (877.78 KB - PDF)

Skatīt

norsk (NO) (860 KB - PDF)

Skatīt
Latest procedure affecting product information:II/0027/G
15/11/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (496.48 KB - PDF)

Skatīt

español (ES) (460.12 KB - PDF)

Skatīt

čeština (CS) (486.03 KB - PDF)

Skatīt

dansk (DA) (460.06 KB - PDF)

Skatīt

Deutsch (DE) (459.93 KB - PDF)

Skatīt

eesti (ET) (459.94 KB - PDF)

Skatīt

ελληνικά (EL) (496.65 KB - PDF)

Skatīt

français (FR) (459.86 KB - PDF)

Skatīt

hrvatski (HR) (472.28 KB - PDF)

Skatīt

italiano (IT) (459.91 KB - PDF)

Skatīt

latviešu (LV) (489.48 KB - PDF)

Skatīt

lietuvių (LT) (474.86 KB - PDF)

Skatīt

magyar (HU) (484.42 KB - PDF)

Skatīt

Malti (MT) (490.05 KB - PDF)

Skatīt

Nederlands (NL) (459.69 KB - PDF)

Skatīt

polski (PL) (489.07 KB - PDF)

Skatīt

português (PT) (459.81 KB - PDF)

Skatīt

română (RO) (930.92 KB - PDF)

Skatīt

slovenčina (SK) (29.59 KB - PDF)

Skatīt

slovenščina (SL) (483.95 KB - PDF)

Skatīt

suomi (FI) (460.2 KB - PDF)

Skatīt

svenska (SV) (459.88 KB - PDF)

Skatīt

Íslenska (IS) (460 KB - PDF)

Skatīt

norsk (NO) (459.61 KB - PDF)

Skatīt

Product details

Name of medicine
Evarrest
Active substance
  • human fibrinogen
  • human thrombin
International non-proprietary name (INN) or common name
  • human fibrinogen
  • human thrombin
Therapeutic area (MeSH)
Hemostasis
Anatomical therapeutic chemical (ATC) code
B02BC30

Pharmacotherapeutic group

Local hemostatics

Therapeutic indication

Supportive treatment in adult surgery where standard surgical techniques are insufficient (see section 5.1):

- for improvement of haemostasis.

Authorisation details

EMA product number
EMEA/H/C/002515
Marketing authorisation holder
Omrix Biopharmaceuticals N. V.

Leonardo Da Vinci Laan 15
1831 Diegem
Belgium

Marketing authorisation issued
25/09/2013
Withdrawal of marketing authorisation
15/11/2017
Revision
4

Assessment history

This page was last updated on

Share this page